SSR 128428 - sanofi-aventis

Drug Profile

SSR 128428 - sanofi-aventis

Alternative Names: SSR-128428; SSR128428E

Latest Information Update: 17 Mar 2009

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antithrombotics; Oligosaccharides
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Thrombosis

Most Recent Events

  • 11 Feb 2009 Phase-I clinical trials in Thrombosis in Europe (unspecified route)
  • 12 Feb 2008 This programme is still in active development
  • 30 Jul 2007 Data presented at the 21st Congress of the International Society on Thrombosis and Haemostasis added to the Thromboses pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top